Crinetics Pharmaceuticals
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company develops non-peptide small molecule drug candidates targeted at g-protein coupled receptors, including clinical programs for acromegaly, neuroendocrine tumors, and Cushing's disease. Revenue is derived primarily from collaboration agreements, licensing arrangements, and capital funding as its pipeline progresses toward commercial launch. Its core end markets comprise endocrinology practices, academic medical centers, and specialized rare disease treatment facilities. Crinetics holds a distinct position in the biopharmaceutical industry through its specialized focus on oral small molecule endocrinology therapies. The company is headquartered in San Diego, California, and its common stock is traded on the Nasdaq Global Select Market.
5 of the funds FundTelligence covers report a position in Crinetics Pharmaceuticals.
- Legal name
- Crinetics Pharmaceuticals Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 5
Funds holding Crinetics Pharmaceuticals
- BNP Health Care Innovators — BNP Paribas · 1.58 % (full portfolio disclosed, June 2026)
- BNP US Small Cap — BNP Paribas · 0.9 % (full portfolio disclosed, June 2026)
- JPM US Small Cap Growth Fund — JPM · 0.82 % (full portfolio disclosed, June 2026)
- SEB Läkemedelsfond — SEB · 0.44 % (full portfolio disclosed, June 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.03 % (partially disclosed portfolio, June 2026)